Shares of Seres Therapeutics Inc. (NASDAQ:MCRB) fell sharply in premarket trading on Thursday, following the company’s announcement of a significant operational shift. The decision to prioritize emerging programs in inflammatory and immune diseases has raised concerns among investors regarding the viability of its current pipeline and funding strategies.
Strategic Shift in Research Focus
Seres has finalized the protocol for its Phase 2 study of SER-155, aimed at patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT). Despite this progress, the company has opted to pause further investment in this program while it seeks additional funding. The new operational focus will target high-value earlier-stage pipeline programs, which include SER-603, a candidate for treating indications such as ulcerative colitis, Crohn’s disease, and immune checkpoint-related enterocolitis (irEC).
In a statement, the company confirmed it will continue to support the read-out of clinical results from the fully enrolled investigator-sponsored SER-155 study for irEC, with results anticipated in the early part of Q2 2026. Discussions are ongoing with potential partners to explore collaborations that could bolster its funding and operational capacity.
Workforce Reduction and Financial Strategy
In conjunction with these strategic changes, Seres Therapeutics announced a workforce reduction of approximately 30%. This move aims to extend the company’s cash runway through the third quarter of 2026, allowing it to concentrate on advancing its early-stage live biotherapeutic programs.
With a current cash balance of $47.6 million, Seres initially projected its funding to sustain operations until the second quarter of 2026. The workforce reduction is seen as a necessary step to ensure resources are optimally allocated during this transitional period.
The broader market reflected mixed performance on the previous trading day, with the Nasdaq gaining 0.32% and S&P 500 futures rising 0.3%. In contrast, Seres’s stock decline highlights company-specific challenges that overshadow a generally positive market environment.
Despite the turmoil, technical indicators suggest a bearish trend for Seres Therapeutics. The stock currently trades 24.4% below its 20-day simple moving average (SMA) and 33% below its 100-day SMA. Over the past year, shares have decreased by 13.86%, positioning the stock closer to its 52-week lows, reflecting ongoing operational challenges.
Moreover, the Relative Strength Index (RSI) stands at 42.50, indicating neutral territory, while the Moving Average Convergence Divergence (MACD) remains below its signal line, suggesting bearish pressure.
As the company navigates these significant changes, it faces an uncertain immediate future while striving to reposition itself within a competitive landscape.
